Most of the surface membrane antigens (CD5, CD11c, CD19, CD20, CD21, CD22, CD23, CD25, CD40, CD45, VD79b, CD80, CD95, CD122, ... The expression of several antigens was co-regulated, suggesting common regulatory pathways. These antigens include CD11c/CD5, ... even when antigens belonged to entirely different gene families. Such antigen pairs were: CD11c/CD21; CD19/CD45; CD19/CD79b; ... Upregulation of surface antigen expression, induced by OMCs, should be applicable in antibody therapy in vitro and in vivo, and ...

Representative examples of CD68 (A, B), plasma cell (C, D), CD8 (E, F), CD20 (G, H) and RANKL (I, J) staining. (A,C,E,G,I) ... Bone samples were processed as previously described.11 Antigen retrieval was achieved with Dako Target Retrieval Solution pH ... A case of germinal center formation by CD45RO T and CD20 B lymphocytes in rheumatoid arthritic subchondral bone: proposal for a ... anti-CD20 (1:200, Dako, clone L26), and anti-tartrate-resistant acid phosphatase (TRAP) (1:100, Zymed, San Francisco, clone ...

Aberrant T-Cell Antigen Expression in Classical Hodgkin Lymphoma is Associated with Decreased Event-Free Survival and Overall ... Peripheral T-cell lymphoma with aberrant expression of CD30, CD15, and CD20. Journal of Clinical Oncology. 2011; 29(32):789-791 ...

The difference of antigen expression as defined by the fluorescent intensity of FCM was significantly clear in CD20 and CD22 ... The difference of antigen expression as defined by the fluorescent intensity of FCM was significantly clear in CD20 and CD22 ... could be considered that the unusual expression or alternation of B cell-lineage antigens and defectiveness of common antigen ... could be considered that the unusual expression or alternation of B cell-lineage antigens and defectiveness of common antigen ...

... and chimeric antigen receptor (CAR) T cells, are changing the treatment paradigm for ALL. Blinatumomab and INO are being ... In general, CD20 positivity is defined as expression of CD20 in greater than or equal to 20% of the blast cells in the NCCN ... CD19 antigen loss has been observed to be a common mechanism of relapse after CD19-directed BiTE and CAR T cell therapies, yet ... CD3 x CD20 full-length BiTE. DuoBody®-CD3xCD20 (GEN3013) is a novel BiTE targeting CD20-expressing B cells [81]. Different from ...

B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase and progressively ... It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug ... This can occur, for example, when an allogeneic transplantation patient develops an immune reaction to donor antigens, or when ... As an alternative strategy to immunosuppression and antigen-specific tolerance inducing therapies, the primary goal of SCIIT is ...

... they should express B-cell antigens such as CD20, CD79a or PAX5.[17] Flow cytometry has also shown promise in aiding the ...

Individuals who have the D antigen on the RBCs are reported to be RhD-positive, whereas those that usually do not are reported ... anti-CD20 for B-cell lymphomas5) and trastuzumab (anti-HER-2/neu for several breast malignancies6). Restorative antibodies ... Chimeric antigen receptors (Vehicles), comprising extracellular antibody fragments aimed against a tumor epitope fused to ... 1C3). Antibodies against tumor-associated epitopes, that are limited by antigens presented for the cell surface area of tumors ...

In the six years following the approval of the first-ever chimeric antigen receptor (CAR) T-cell therapy in 2017, the treatment ... CD19 and CD20. By targeting two different antigens, the risk of antigen escape is lowered, and patients remain in remission ... The patients immune system cells are then sent to a lab where researchers modify them with a gene for a chimeric antigen ... In the six years following the approval of the first-ever chimeric antigen receptor (CAR) T-cell therapy in 2017, the treatment ...

... with frequent CD38 and CD138 co-expression in the absence of earlier B cell antigens such as CD19, CD20, CD22, CD79a and CD79b ...

... replacement in CAR T cell therapy are extrapolated from patients with hematologic malignancy who received anti-CD20 monoclonal ... Toxicity of Chimeric Antigen Receptor T Cells and its Management. Kitsada Wudhikarn1, Shui Yen Soh2, He Huang3, Miguel-Angel ... Chimeric antigen receptor (CAR) T cells are engineered T cells that are transduced to express an artificially modified receptor ... As CD19, CD22, and other antigens targeted by CAR T cells are widely expressed by B cells, B cell aplasia is an unavoidable off ...

Mice were injected with the anti-CD20 monoclonal antibody 5D2, 14 days before or 14 days after infection with TMEV. Efficacy of ... We sought to discover what effect BCD, induced by an anti-CD20 monoclonal antibody, would have on Theilers murine ... B cell depletion, Disability progression, Multiple sclerosis, TMEV-IDD, Animals, Antibodies, Antibody Formation, Antigens, CD20 ... We sought to discover what effect BCD, induced by an anti-CD20 monoclonal antibody, would have on Theilers murine ...

Monoclonal antibodies target antigens expressed by lymphoma cells, making them more selective than chemotherapy. As exemplified ... while the binding site induces downregulation of the B-cell receptor and apoptosis in CD20+ cells. ... by rituximab, which targets CD20 present on B-cells, the Fc portion of the antibody mediates cytotoxicity, ...

For example, in prostate cancer, a biCAR was constructed with two prostate cancer antigens (prostate-specific membrane antigen ... Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20- ... This special biCAR effectively targeted tissues expressing both antigens but not tissues positive with single antigen [89]. ... IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent ...

Antibodies against carbohydrate antigens on red blood cells and against measles were quantified. Before treatment, ... CD20+CD27+IgM+, 13.0% versus 2.0%, p,0.001). The percentage of memory T-cells, mainly early effector/memory T-cells, was higher ... Antibodies against carbohydrate antigens on red blood cells and against measles were quantified. Before treatment, ... Antibodies against carbohydrate antigens on red blood cells and against measles were quantified. Before treatment, ...

The number of CD20+-cells, being a subpopulation of B-lymphocytes, was not different from normal values, but at the same time ... and B-lymphocytes was determined by immunofluorescence method with monoclonal antibodies to differentiation lymphocyte antigens ... CD3, CD4, CD8, CD20; content of various classes immunoglobulins - using a method of radial immune diffusion in a gel using ...

CD20 or CD22) or both antigens simultaneously, as well as IFNg release in response to antigen specific stimulation. ... UCART20x22 is Cellectis first dual allogeneic CAR T-cell product candidate targeting both CD20 and CD22 and is being evaluated ... against targets expressing heterogeneous levels of CD22 and CD20. We have used in vitro cytotoxicity assays against different ... while efficiently targeting primary Non-Hodgkin Lymphoma samples with heterogeneous levels of CD20 and CD22. ...

... genetics.2 The immunophenotype is characterized by term of CD5 and the B cellCassociated YM201636 antigens CD20, CD22, CD79, ...

... enabling coincident targeting of CD19 and additional tumor-associated antigens such as CD20. FT596 also expresses an ... and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product ... "Current patient- and donor-specific CAR T-cell immunotherapies recognize only one antigen and fail to address the significant ... These data confirm previously presented in vitro findings that demonstrate the unique multi-antigen targeting functionality of ...

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer ... Antigen escape is an emerging threat to CAR T-cell therapy. One mechanism of antigen escape is the presence of non-functional ... Similar to targeting CD19 antigen in B-cell malignancies, B-cell maturation antigen (BCMA) is used as the TAA for CAR T-cell ... one CAR T-cell is designed to bind to more than one antigen (15, 26). For example, CD19-OR-CD20 CAR T-cells were developed and ...

CD45, EMA, ALK1, CD3, CD45RO, CD4, CD8, CD20, CD30, CD15 and cytotoxic antigens (TIA1, perforin). ... CD15, CD20, CD30, CD43, CD45, ALK, CD57 and EMA. Anaplastic large-cell lymphoma. ... Dense CD20+, CD79+ B cells and CD10+ cells in the interfollicular region. ... CD45, CD20, CD3, CD43, MIB1, BCL-2, MUM1, CD10 and BCL-6. ... CD20 and CD79a. Markers of T lymphocytes. CD45RO, MT1, CD3, ...

Recipients of an anti-CD20 agent (examples include rituximab, ocrelizumab, ofatumumab). * Residents of Long-Term Care Homes ( ... Those who are in receipt of chimeric antigen receptor (CAR)-T-cell; ... CD20 and CD22), high-dose systemic corticosteroids, alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) ...

Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells[J ... target antigen selection such as less tumor toxicity and antigen escape, T cell homing to the tumor, T cell infiltration into ... An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for ... Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. The New England Journal of Medicine, 2013, 368(16): ...

Antigen-specific CD8+ T cell responses were variable, but also trended upward in PD-L1 KO and PD-L1ΔDC mice (a trend separately ... Tong et al. evaluated multiple variants of bispecific scFv CAR T cells (TanCAR) targeting CD19 and CD20, and selected TanCAR7 ... Together, these experiments showed that PD-L1 expression on antigen-presenting cells (APCs) played a role in antitumor T cell ... Waite et al. demonstrated that two different "costimulatory bispecifics" cross-linking CD28 to a tumor-specific antigen (PSMA ...

Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves hyperthyroidism: a phase I study. Thyroid 2019;29: ... A chimeric antibody against CD20 (rituximab) showed some therapeutic effects in GO but not in GD [59,60]. Drugs for treating GO ... antigen) of the TSH receptor, are activated by cytokines that cause inflammation, autoantibodies against the TSH receptor are ... an immunotherapeutic agent specific for the TSH receptor peptide antigen, has been shown to have positive effects against GD in ...

... which is a kind of immunotherapy or targeted therapy and attacks the CD20 antigen on the cancer cells. ... hemo-immunotherapy: Rituximab which is anti CD20 monoclonal antibody, which can specifically attack lymphoma/ CLL cells along ... Rituximab should be used depending upon CD20 expression on lymphoma cells. *Chemotherapies: usually high intensity combination ... Most important aspect of therapy is anti CD20 antibody, the Rituximab, ...

... a chimeric murine-human monoclonal antibody directed against B lymphocyte specific antigen CD20. Rituximab treatment decreased ...

LP cells typically have immunophenotypic staining positive for CD-20, BCL-6 (B cell lymphoma), and epithelial membrane antigen ... protein and epithelial membrane antigen (EMA), which were consistent with a diagnosis of nodular lymphocyte-predominant Hodgkin ... protein and epithelial membrane antigen (EMA), which were consistent with a diagnosis of nodular lymphocyte-predominant Hodgkin ... CD-20, and EMA, consistent with a diagnosis of NLPHL. He received site radiation therapy with a total dose of 3600 centigray ( ...

Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 2018; 24 Suppl 2:S71. ... Ofatumumab - Ofatumumab is a fully human monoclonal anti-CD20 monoclonal antibody, which targets a distinct epitope on the CD20 ... The first involves direct binding of the T cell antigen receptor by antigenic peptide presented by antigen-presenting cells ( ... Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). ...

... by the diffusion of payload delivered to antigen-positive cells into neighboring antigen-negative cells. In the case of DF, the ... binds human but not murine CD20), except for OV2423, CTG-1692, and mBR9013 studies, in which the nonbinding control was ... 1B). Antigen binding was comparable for the ADCs as well as the unconjugated antibody (Supplementary Fig. S1A). Similarly, ... Manual antigen unmasking was done using heat induced epitope retrieval with an electronic pressure cooker. Slides were immersed ...